(E)-6-甲基吡啶甲醛肟 | 1265324-16-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (E)-6-甲基吡啶甲醛肟
• 英文名称: (E)-6-methylpicolinaldehyde oxime
• 英文别名: 6-Methyl-pyridin-2-aldehyd-oxim；6-Methylpyridine-2-carbaldehyde oxime；(NE)-N-[(6-methylpyridin-2-yl)methylidene]hydroxylamine
• CAS: 1265324-16-0
• 化学式: C₇H₈N₂O
• 分子量: 136.153
• InChiKey: OIKGFMHISSQNRL-VMPITWQZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-6-甲基吡啶甲醛肟 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 反应 12.0h， 生成 6-甲基-2-吡啶甲胺
  参考文献：
  名称：

  高自旋镍 (II) 配合物的顺磁 NMR 研究。双核与单核物种的受控合成、结构、电子和磁特性

  摘要：

  已合成具有不同 N/S 供体集的新不对称叔胺 (N(3)SR) 以提供单核和双核配合物。乙酸根离子用于完成围绕镍 (II) 原子的八面体配位球。可以控制单核系统向双核系统的轻松转化，以从同一配体产生单核或双核复合物。双核复合物 a(BPh(4))(2) ([Ni(2)(N(3)SSN(3))(OAc)(2)](BPh(4))(2))固态通过 X 射线衍射技术作为溶剂化物：a(BPh(4))(2).(1/2)[5(CH(3)OH).(CH(3)CN).(CH(3) )CH(2)OH)]。两个 Ni 原子是六配位的，并由一个二硫化物基团和两个双齿乙酸酯桥接。磁化率揭示了 J = 2.5(7) cm(-1) 的两个 Ni 原子之间的弱铁磁交换相互作用。UV-vis 研究表明六配位结构在溶液中持续存在。a(BPh(4))(2) 的 (1) H 核磁共振谱表现出明显的超精细移位配体信号。完整的共振分

  DOI：

  10.1021/ja010342k
• 作为产物：
  描述：

  2,6-二甲基吡啶 N-氧化物 在 manganese(IV) oxide 、 盐酸羟胺 、 potassium carbonate 、 三氟乙酸酐 作用下， 以 甲醇 、 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 反应 73.0h， 生成 (E)-6-甲基吡啶甲醛肟
  参考文献：
  名称：

  Methyl Scanning and Revised Binding Mode of 2-Pralidoxime, an Antidote for Nerve Agent Poisoning

  摘要：

  Organophosphorus nerve agents (OPNAs) inhibit acetylcholinesterase (AChE) and, despite the Chemical Weapons Convention arms control treaty, continue to represent a threat to both military personnel and civilians. 2-Pralidoxime (2-PAM) is currently the only therapeutic countermeasure approved by the United States Food and Drug Administration for treating OPNA poisoning. However, 2-PAM is not centrally active due to its hydrophilicity and resulting poor blood-brain barrier permeability; hence, these deficiencies warrant the development of more hydrophobic analogs. Specifically, gaps exist in previously published structure activity relationship (SAR) studies for 2-PAM, thereby making it difficult to rationally design novel analogs that are concomitantly more permeable and more efficacious. In this study, we methodically performed a methyl scan on the core pyridinium of 2-PAM to identify ring positions that could tolerate both additional steric bulk and hydrophobicity. Subsequently, SAR-guided molecular docking was used to rationalize hydropathically feasible binding modes for 2-PAM and the reported derivatives. Overall, the data presented herein provide new insights that may facilitate the rational design of more efficacious 2-PAM analogs.

  DOI：

  10.1021/acsmedchemlett.9b00586

文献信息

• [EN] SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS SPHINGOSINE-1-PHOSPHATE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011017578A1

  公开（公告）日：2011-02-10

  Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  揭示了Formula (I)的化合物，或其立体异构体或药用可接受的盐，其中：A为Formula (II)，Q为取代的5-成员单环杂芳基团；W为CH2、O或NH；而R1、R2、R3、R4、R5、R6、m、n、t和x在此处有定义。还揭示了将这些化合物用作G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或紊乱方面具有用处，如自身免疫疾病和血管疾病。
• Aminoheteroaryl benzamides as kinase inhibitors
  申请人：Bagdanoff Jeffrey T.

  公开号：US09242996B2

  公开（公告）日：2016-01-26

  The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

  本发明提供了化合物的化合物（I）或其盐； 以及这些化合物的治疗用途。本发明还提供了包含这些化合物的药物组合物，以及包含这些化合物与治疗辅助剂的组合物。
• Substituted imidazoles as bombesin receptor subtype-3 modulators
  申请人：Dobbelaar Peter H.

  公开号：US20100204236A1

  公开（公告）日：2010-08-12

  Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

  某些新型取代咪唑是人类炸弹肽受体的配体，特别是人类炸弹肽受体亚型-3（BRS-3）的选择性配体。因此，它们可用于治疗、控制或预防对BRS-3调节敏感的疾病和障碍，例如肥胖症和糖尿病。
• HETEROCYCLIC COMPOUNDS
  申请人：Gilmore John L.

  公开号：US20110190255A1

  公开（公告）日：2011-08-04

  Disclosed are compounds of Formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is Q is a substituted 5-membered monocyclic heteroaryl group; W is CH 2 , O, or NH; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P 1 , and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及化合物I式或其立体异构体或其药学上可接受的盐，其中：A为Q为取代的5-成员单环杂芳基；W为CH2、O或NH；R1、R2、R3、R4、R5、R6、m、n、t和x在此定义。本发明还涉及使用这些化合物作为选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面是有用的，如自身免疫性疾病和血管疾病。
• Heterocyclic compounds
  申请人：Gilmore John L.

  公开号：US08399451B2

  公开（公告）日：2013-03-19

  Disclosed are compounds of Formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式(I)化合物或其立体异构体或其药学上可接受的盐，其中：A是Q是取代的5-成员单环杂芳基基团；W是CH2、O或NH；R1、R2、R3、R4、R5、R6、m、n、t和x在此被定义。本发明还涉及使用这些化合物作为选择性G蛋白偶联受体S1P1激动剂的方法，以及包含这些化合物的药物组成物。这些化合物在多种治疗领域中有用，如自身免疫病和血管疾病的治疗、预防或减缓进展。

表征谱图